论文部分内容阅读
目的观察吉非替尼治疗晚期非小细胞肺癌患者的近期疗效和毒性反应。方法23例晚期非小细胞肺癌进入本研究。吉非替尼剂量为250mg/次,口服,1次/d。全组服药的平均时间为6.13个月。结果毒副作用主要为皮疹9例(40.91%);腹泻3例(13.64%),1例因腹泻严重而停药;转氨酶升高1例(4.51%)。22例患者参与疗效评价,治疗后获完全缓解1例,部分缓解5例,稳定12例,进展4例。全组有效率为27.27%,疾病控制率为81.82%。结论吉非替尼在晚期非小细胞肺癌的治疗中有一定的疗效和良好的耐受性。
Objective To observe the short-term curative effect and toxicity of gefitinib in patients with advanced non-small cell lung cancer. Methods Twenty-three patients with advanced non-small cell lung cancer entered the study. Gefitinib dose of 250mg / time, orally, 1 / d. The average time for the whole group was 6.13 months. Results The main side effects were rash in 9 cases (40.91%), diarrhea in 3 cases (13.64%), and discontinuation of one case due to severe diarrhea. Elevated aminotransferases were found in 1 case (4.51%). Twenty-two patients were involved in the evaluation of the curative effect. One patient was completely relieved after treatment, 5 patients were partially relieved, 12 patients were stable, and 4 patients were advanced. The total effective rate was 27.27%, disease control rate was 81.82%. Conclusion Gefitinib has some curative effect and good tolerance in the treatment of advanced non-small cell lung cancer.